Localized versus systemic granulomatosis with polyangiitis: data from the French Vasculitis Study Group Registry.


Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
30 05 2022
Historique:
received: 06 07 2021
revised: 08 09 2021
pubmed: 21 9 2021
medline: 3 6 2022
entrez: 20 9 2021
Statut: ppublish

Résumé

To describe the main features at diagnosis and evolution over time of patients with localized granulomatosis with polyangiitis (L-GPA) compared with those of systemic GPA (S-GPA). EULAR definitions of L-GPA, i.e. upper and/or lower respiratory tract involvement, and S-GPA were applied to patients from the French Vasculitis Study Group Registry. L-GPA and S-GPA patients' characteristics at diagnosis and long-term outcomes were analysed and compared. Among the 795 Registry patients, 79 (10%) had L-GPA. Their main clinical manifestations were rhinitis, lung nodules, sinusitis and otitis. L-GPA vs S-GPA patients at diagnosis, respectively, were younger, more frequently had saddle nose deformity or subglottic stenosis and were less often PR3-ANCA-positive. L-GPA vs S-GPA induction therapy less frequently included CYC but more often a combination of MTX and glucocorticoids; 64% of MTX-treated patients experienced disease progression within 18 months post-diagnosis. L- and S-GPA patients' estimated relapse-free-survival probabilities, relapse rates and refractory disease rates at each time point were comparable, but L-GPA patients had more frequent ENT and lung relapses, and higher overall survival rates (P<0.02). Over a median follow-up of 3.5 years, 18 (22.8%) L-GPA progressed to S-GPA, either as a relapse after a period in remission or more frequently in the context of refractory disease. L-GPA patients experienced more ENT-related damage. The relapse risks of L-GPA and S-GPA were similar, but relapse patterns differed and L-GPA overall survival rate was higher. About one-quarter of L-GPA patients developed S-GPA over time, but without end-stage organ involvement.

Identifiants

pubmed: 34542599
pii: 6372709
doi: 10.1093/rheumatology/keab719
doi:

Substances chimiques

Antibodies, Antineutrophil Cytoplasmic 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2464-2471

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Michele Iudici (M)

National Referral Center for Rare Systemic Autoimmune Diseases, Université de Paris, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
Division of Rheumatology, Department of Internal Medicine Specialties, Geneva University Hospitals, Switzerland.

Christian Pagnoux (C)

National Referral Center for Rare Systemic Autoimmune Diseases, Université de Paris, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.

Delphine S Courvoisier (DS)

Division of Rheumatology, Department of Internal Medicine Specialties, Geneva University Hospitals, Switzerland.

Pascal Cohen (P)

National Referral Center for Rare Systemic Autoimmune Diseases, Université de Paris, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.

Antoine Néel (A)

Department of Internal Medicine, Centre Hospitalier Universitaire (CHU) Hôtel-Dieu, Nantes.

Achille Aouba (A)

Department of Internal Medicine, CHU Côte-de-Nacre, Caen.

François Lifermann (F)

Department of Internal Medicine, CH Côte-d'Argent, Dax.

Marc Ruivard (M)

Department of Internal Medicine, CHU Estaing, Clermont-Ferrand.

Olivier Aumaître (O)

Department of Internal Medicine, CHU Estaing, Clermont-Ferrand.

Bernard Bonnotte (B)

Department of Internal Medicine, CHU François Mitterrand, Dijon.

François Maurier (F)

Service of Internal Medicine, Groupe Hospitalier UNEOS, Metz-Vantoux.

Thomas Le Gallou (T)

Department of Internal Medicine and Immunology, CHU, Rennes.

Eric Hachulla (E)

National Referral Center for Rare Systemic Autoimmune Diseases, Department of Internal Medicine and Clinical Immunology, CHU Claude Huriez, Lille.

Alexandre Karras (A)

Department of Nephrology, Hôpital Européen Georges-Pompidou, APHP, Paris.

Chahéra Khouatra (C)

Department of Respiratory Medicine, CHU Louis-Pradel and UMR754, Université Claude-Bernard Lyon 1, Lyon.

Noémie Jourde-Chiche (N)

Department of Nephrology, Aix-Marseille Univ, C2VN, INSERM 1263, INRAE 1260, APHM, CHU de la Conception, Marseille.

Jean-François Viallard (JF)

Department of Internal Medicine, CHU Haut-Lévêque, Bordeaux.

Claire Blanchard-Delaunay (C)

Department of Internal Medicine, CH, Niort.

Pascal Godmer (P)

Department of Internal Medicine, CH Bretagne-Atlantique, Vannes.

Alain Le Quellec (A)

Department of Internal Medicine, CHU Saint-Eloi, Montpellier.

Thomas Quéméneur (T)

Department of Nephrology and Internal Medicine, CH, Valenciennes.

Claire de Moreuil (C)

Department of Internal Medicine, CHU La Cavale Blanche, Brest, France.

Alexis Régent (A)

National Referral Center for Rare Systemic Autoimmune Diseases, Université de Paris, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.

Benjamin Terrier (B)

National Referral Center for Rare Systemic Autoimmune Diseases, Université de Paris, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.

Luc Mouthon (L)

National Referral Center for Rare Systemic Autoimmune Diseases, Université de Paris, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.

Loïc Guillevin (L)

National Referral Center for Rare Systemic Autoimmune Diseases, Université de Paris, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.

Xavier Puéchal (X)

National Referral Center for Rare Systemic Autoimmune Diseases, Université de Paris, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH